APELLIS PHARMACEUTICALS INC

NASDAQ: APLS (Apellis Pharmaceuticals, Inc.)

Last update: 04 Sep, 2:51PM

38.02

-0.78 (-2.02%)

Previous Close 38.80
Open 38.60
Volume 847,602
Avg. Volume (3M) 1,424,662
Market Cap 4,628,934,656
Price / Sales 5.33
Price / Book 12.64
52 Weeks Range
33.49 (-11%) — 73.80 (94%)
Earnings Date 30 Oct 2024 - 4 Nov 2024
Profit Margin -52.94%
Operating Margin (TTM) -14.75%
Diluted EPS (TTM) -2.72
Quarterly Revenue Growth (YOY) 110.30%
Total Debt/Equity (MRQ) 179.52%
Current Ratio (MRQ) 5.08
Operating Cash Flow (TTM) -408.28 M
Levered Free Cash Flow (TTM) -336.11 M
Return on Assets (TTM) -21.51%
Return on Equity (TTM) -109.19%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Apellis Pharmaceuticals, Inc. Bearish Bearish

Stockmoo Score

0.9
Analyst Consensus 1.5
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 2.5
Technical Oscillators -2.5
Average 0.88

Similar Stocks

Stock Market Cap DY P/E P/B
APLS 5 B - - 12.64
CRNX 5 B - - 5.60
KRYS 5 B - 45.24 6.06
RARE 5 B - - 11.25
AXSM 4 B - - 42.94
ACLX 4 B - - 9.38

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 14.28%
% Held by Institutions 97.25%
52 Weeks Range
33.49 (-11%) — 73.80 (94%)
Price Target Range
35.00 (-7%) — 92.00 (142%)
High 92.00 (Baird, 142.01%) Buy
Median 74.00 (94.66%)
Low 35.00 (Scotiabank, -7.93%) Hold
Average 64.64 (70.04%)
Total 7 Buy, 4 Hold
Avg. Price @ Call 34.21
Firm Date Target Price Call Price @ Call
Mizuho 24 Oct 2024 38.00 (-0.04%) Hold 27.58
20 Sep 2024 39.00 (2.59%) Hold 32.51
Scotiabank 16 Oct 2024 35.00 (-7.93%) Hold 27.95
Wells Fargo 24 Sep 2024 43.00 (13.11%) Hold 30.75
Baird 23 Sep 2024 92.00 (142.01%) Buy 32.72
09 Aug 2024 96.00 (152.53%) Buy 37.01
Needham 20 Sep 2024 85.00 (123.60%) Buy 32.51
09 Aug 2024 85.00 (123.60%) Buy 37.01
JP Morgan 13 Sep 2024 57.00 (49.94%) Buy 37.62
13 Aug 2024 64.00 (68.35%) Buy 35.72
Goldman Sachs 09 Aug 2024 74.00 (94.66%) Buy 37.01
02 Aug 2024 66.00 (73.62%) Buy 36.56
UBS 09 Aug 2024 83.00 (118.33%) Buy 37.01
Wedbush 09 Aug 2024 41.00 (7.85%) Hold 37.01
HC Wainwright & Co. 02 Aug 2024 83.00 (118.33%) Buy 36.56
Jefferies 31 Jul 2024 80.00 (110.44%) Buy 39.60
Show more

No data within this time range.

Date Type Details
26 Oct 2024 Announcement Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
22 Oct 2024 Announcement Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
16 Oct 2024 Announcement Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
04 Oct 2024 Announcement Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 Sep 2024 Announcement Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
20 Sep 2024 Announcement Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
06 Sep 2024 Announcement Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Aug 2024 Announcement Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
08 Aug 2024 Announcement Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
08 Aug 2024 Announcement Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
06 Aug 2024 Announcement Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2024 Announcement Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria